{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-021801","form_type":"8-K","ticker":"AXSM","cik":"0001579428","company_name":"Axsome Therapeutics, Inc.","filed_at":"2025-02-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.059415+00:00","generated_at":"2026-05-26T16:24:30.487177+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Axsome Q4/FY24 revenue $118.8M/$385.7M; Auvelity growth 124% YoY; Symbravo approved; pipeline NDA submissions on track","bullets":["Total net product revenue FY24 $385.7M (+88%); Q4 $118.8M (+66% YoY).","Auvelity net sales FY24 $291.4M (+124%); Q4 $92.6M (+89% YoY).","Symbravo approved Jan 30, 2025 for acute migraine; commercial launch in ~4 months.","Patent settlement with Teva extends Auvelity generic entry to 2038–2039; license with pediatric exclusivity.","AXS-05 (Alzheimer's agitation) and AXS-12 (narcolepsy) NDA submissions on track for 2H 2025; AXS-14 NDA submission in 1Q 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-021801","json":"https://secwatch.observer/filing/0000950170-25-021801.json","markdown":"https://secwatch.observer/filing/0000950170-25-021801.md","text":"https://secwatch.observer/filing/0000950170-25-021801.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1579428/000095017025021801/0000950170-25-021801-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1579428/000095017025021801/axsm-20250218.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T16:24:30.487177+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}